{"filing":{"accession_number":"0001104659-26-078823","cik":"0001875558","ticker":"NVCT","company_name":"Nuvectis Pharma, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tm2618981d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926078823/tm2618981d2_8k.htm"},"events":[{"id":14633,"run_id":13035,"accession_number":"0001104659-26-078823","anchor_item_number":"8.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"summary":"The Company reduced the available sales capacity under its ATM (at-the-market) offering from an unspecified prior amount to $5 million and suspended the Sales Agreement Prospectus effective June 29, 2026. This represents a material reduction in the Company's access to capital markets and signals potential liquidity constraints or a shift in financing strategy. While not a traditional debt issuance or dilutive equity placement, this capital-raising modification is a financial event material to investor assessment of the registrant's liquidity position.","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12115,"accession_number":"0001104659-26-078823","item_number":"8.01","item_title":"Other Events.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The Company reduced the available sales capacity under its ATM (at-the-market) offering from an unspecified prior amount to $5 million and suspended the Sales Agreement Prospectus effective June 29, 2026. This represents a material reduction in the Company's access to capital markets and signals potential liquidity constraints or a shift in financing strategy. While not a traditional debt issuance or dilutive equity placement, this capital-raising modification is a financial event material to investor assessment of the registrant's liquidity position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:11:36.957692+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12115,"accession_number":"0001104659-26-078823","item_number":"8.01","item_title":"Other Events.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The Company reduced the available sales capacity under its ATM (at-the-market) offering from an unspecified prior amount to $5 million and suspended the Sales Agreement Prospectus effective June 29, 2026. This represents a material reduction in the Company's access to capital markets and signals potential liquidity constraints or a shift in financing strategy. While not a traditional debt issuance or dilutive equity placement, this capital-raising modification is a financial event material to investor assessment of the registrant's liquidity position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:11:36.957692+00:00","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-29"}]}